CagriSema
CagriSema
Also known as: Cagrilintide/Semaglutide, NNC9204-1706 + Semaglutide
Overview
Key Facts
Primary Goal: Research and therapeutic applications of CagriSema
Cagrilintide activates amylin receptors in the brainstem to reduce appetite. Semaglutide activates GLP-1 receptors for additional appetite suppression.
Dosing Information
~5-7 days (both components)
2.4–2.4 mg
Once weekly (semaglutide component; cagrilintide 2.4 mg)
Ongoing / indefinite under medical supervision
Benefits
- Projected weight loss exceeding 25% of body weight
- Dual appetite suppression via amylin and GLP-1 pathways
- Improved glycemic control
- Single weekly injection for convenience
- Potential superiority over semaglutide alone
Side Effects
Mechanism of Action
Cagrilintide activates amylin receptors in the brainstem to reduce appetite
Semaglutide activates GLP-1 receptors for additional appetite suppression
Dual mechanism slows gastric emptying more effectively than either agent alone
Combined effect on hypothalamic satiety centres for synergistic weight loss
Contraindications
Do not use this peptide if any of the following apply:
- Personal or family history of medullary thyroid carcinoma
- MEN2 syndrome
- Severe pancreatitis history
- Severe gastrointestinal motility disorders
Storage & Reconstitution
Unreconstituted (Powder)
Reconstituted (Mixed)
Research Summary
Phase 2 results showed CagriSema produced approximately 15.6% weight loss at 32 weeks, significantly exceeding the individual components. The Phase 3 REDEFINE trial programme is evaluating the combination across multiple obesity and diabetes populations. Early data suggest potential for >25% weight loss with extended treatment. Novo Nordisk positions CagriSema as a next-generation obesity therapy.
Frequently Asked Questions
Common questions about CagriSema
UK-Specific Information
Exclusive data points and guidance for UK residents using CagriSema
UK Lab Testing
UK Lab Testing
Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)
Why this matters: UK-specific lab testing guidance not available on US competitor sites
Commonly Stacked With
5-Amino-1MQ
Research and therapeutic applications of 5-Amino-1MQ
Ac-SDKP
Research and therapeutic applications of Ac-SDKP
ACE-031
Research and therapeutic applications of ACE-031
Acetyl Hexapeptide-3
Research and therapeutic applications of Acetyl Hexapeptide-3
AHK-Cu
Research and therapeutic applications of AHK-Cu
Alcohol Prep Pads
Research and therapeutic applications of Alcohol Prep Pads
Note: Peptide stacking should only be done under the guidance of a qualified healthcare professional. Individual responses may vary.
Share on TikTok
Generate a trackable link to share this peptide information on TikTok